कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय
Headquarters'
पंचदीप भवन सी॰आई॰जी॰ रोड, नई दिल्ली-110002
PANCHDEEP BHAWAN, C.I.G. MARG, NEW DELHI-110 002
Phone: 011-23604700 Email : dir-gen@esic.nic.in
Website : www.esic.nic.in / www.esic.in

U-25/12/Standing Committee/2022-Med.V (e-100544)/148 Dt:15.04.25
22

To

Deans/Medical Superintendents PGIMSR's/MC/Hospital
Regional Directors, SMO's ESIC
DIMS, ESIS All States/UT's

विषय: ई॰एस॰आई संस्थानों द्वारा प्राप्त दवाओं की गुणवत्ता का परीक्षण - तत्संबंधी।

Sub: Testing of Quality of Drugs received by ESI Institutions - reg.

Ref: ESIC Hqrs Web uploads (Console no. 61/2015 dated 21.01.2015, Console no. 8346/2021 dated 08.09.2021, Console no. 15630/2024 dated 17.01.2024, Console no.15922/2024 dated 13.02.2024, Console no.16045/2024 dated 27.02.2024, Console no. 17954/2024 dated 16.08.2024, Console no. 18257/2024 dated 20.09.2024, Console no.18443/2024 dated 09.10.2024 and Console no. 20150/2025 dated 10.03.2025).

Sir/Madam,

Reference captioned subject, it is informed that maintenance of Quality plays a very important role in drugs issued to ESIC beneficiaries. The lack of following due procedure of quality checks in r/o drugs received by the ESI Institutions have been viewed seriously by HQRS.

In this context, kind attention is again drawn towards the followings:

A. **Quality Control of Drugs purchased through DG-ESIC Rate Contract:**

- Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.
- Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ bidder at regular interval to maintain and ensure the quality of drugs

B. **Quality Control of Drugs purchased through Jan Aushadhi (PMBI):**

- All the drugs batches supplied by PMBI are duly pre-tested by NABL empanelled lab.
- In any case of quality suspicion observed by ESI Institution/s, the lab reports shall be provided on demand to ESIC & ESIS Institutions by PMBI.
- Regular and random testing of the drugs will be under taken by ESI at

regular interval from Govt./Govt. approved laboratories.

- ESIC and ESIS Institution reserve the right to test the supplied goods and will send random sample for testing to ensure the quality of supplied drugs, if there is any suspicion.

C. **Quality Control of Drugs purchased through GeM (CPSE drugs):**

- All drugs purchased through GeM Portal from CPSU firms under Pharmaceutical Purchase Policy are to be sent for random testing through Govt. Labs/Govt. approved Labs.
- Action for drugs declared Not of Standard Quality 'NSQ' on testing to be undertaken as per:

A. General Terms & Conditions of GeM and
B. Terms & Conditions of GeM for CPSU Drugs

- Issues related to Quality (NSQ) on procurement through GeM Portal, NSQ will be reported by user unit to GeM and ESIC, HQRS office.

In reference to above, it has been observed that ESI Institutions are not sending samples for testing regularly &/or submitting information of samples sent for testing to ESIC Hqrs office for which instructions were already issued vide ESIC Hqrs letters dated 21.01.2015, 08.09.2021, 17.01.2024, 13.02.2024, 27.02.2024, 16.08.2024, 20.09.2024, 09.10.2024, 10.03.2025 (copies enclosed).

It is again reiterated that:

1. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.
2. Acceptance of supply of all batches of drugs (Indian/Imported) procured through valid DG ESIC Rate Contracts should mandatorily be accompanied with In-House testing report and the same should be checked at Inspection by the nominated Inspecting officers.
3. Regular and random testing of the drugs supplied by the Jan Aushadhi (PMBI) Authorized distribution channel partners at regular interval.
4. All ESI Institutions should mandatorily send batches of drugs procured through valid DG ESIC Rate Contracts as samples for testing regularly to Govt./Govt. approved Laboratories, in adherence to terms & conditions of respective valid DG ESIC Rate Contract/s.
5. The quantity of batch/sample sent for testing and the receipt thereof, should be as per terms and conditions governing the local contracts for Testing, of respective Institution.
6. The stock of respective drugs for which batches/samples have been sent for Quality testing, should be released for consumption after the receipt of Quality report.
7. The selection of samples sent for testing should be done prudently by the Medical Store keeping in context the Inventory Stock position, supply orders in pipeline, buffer stock (online information on ESIC website etc such that under no circumstances the withholding of the respective Batch sent for Testing till the receipt of report should result in 'Stock out' of the

respective drug/s or result in frivolous Local Purchase.

8. It is mandatory to maintain records for both the samples sent for Testing by the Institution as well as that collected by the State Drug Inspector (as the case maybe).
9. Simultaneously, the information of the drugs sent for Testing and samples collected by the State Drug Inspector (as the case maybe) should be forwarded to the office of the Medical Commissioner of respective Zone and Med V Rate Contract Division, ESIC Hqrs office in the format below, by 5th of each coming month in soft copy (Excel Format only) to dmc-rc@esic.nic.in from the official ID of the Head of the Institution:

Name of ESI Institution: _____

S. No.	Reference (RC No./ GeM/ PMBI)	Name of Pharmaceutical firm	Name of Item	Item No. Page No. of RC etc..	Drug License no. and Place of production	Batch No.	D.O Mfg. & D.O Expiry	Date of Sampling

10. ESI Institutions should mandatorily check ESIC website for the uploads regarding samples sent for testing. If authentic information regarding submission of specific batch of sample sent for testing is available with user unit, the same batch may not be sent for testing again.
11. For all samples declared "Not of Standard Quality", information along with self-attested copy of the Test Report duly countersigned by Dy. Medical Superintendent/Medical Officer Incharge of Store should be sent to ESIC Hqrs office in the format given below with in a period of five days form the date of receipt of report

Name of ESI Institution: _____

S. No.	Reference (RC No./ GeM/ PMBI)	Name of Pharmaceutical firm	Name of Item	Item No. Page No. of RC etc..	Batch No.	D.O Mfg. & D.O Expiry	Date of Sampling	Name of Laboratory/ Govt. agency reporting the NSQ	Report No. and Date

12. The data for samples sent for Testing from all ESI institutions within the respective State and any NSQ reported thereof should be mandatorily also sent to the office of the Medical Commissioner of the respective zone.
13. All ESI Institutions should initiate penal action (replacement of batch of drug with a different batch/ recovery deduction of testing charges etc) as per terms and conditions of the DG ESIC /CPSE(GeM)/ Jan Aushadhi (PMBI).
14. Quality assurance of drugs is not only an essential clause in the terms & conditions of the Rate Contracts/CPSE(GeM)/ Jan Aushadhi (PMBI) but also plays a vital role in maintaining distribution of life saving drugs to patients.

The above instructions are for mandatory adherence by all Heads of Institutions. Any legal repercussion arising in respect to non-adherence of Quality shall lie solely with the Heads of Institution.

This issues with the approval of Medical Commissioner (Procurement).

Warm regards,

Digitally signed by Sanjiv Kochhar
Date: 21-04-2025 17:21:19

Dy. Medical Commissioner (RC)

Enclosures: As above

copy for information to:

1. Medical Commissioner (North -East, South Zone, West Zone, East Zone, North Zone) for information.
2. ICT Division of ESIC HQ is again requested to create a separate section on ESIC Website for updating information pertaining to drugs sent for testing by ESI/Sample collected by Drug Department from ESI Institutions.
3. Website Content Manager with request for uploading on ESIC Website.
4. Guard File

HQRS. OFFICE
EMPLOYEES' STATE INSURANCE CORPORATION
PANCHDEEP BHAWAN: C.I.G. ROAD: NEW DELHI – 110 002
TelFax: 011-23234334, E-mail: dmc-rc@esic.nic.in
(An ISO-9001:2008 Certified)

No: U-25/12/Drug Policy/2014-Med V/Pt-I/04 Dated: 21/01/2015

To,

Director (Medical) Delhi/Noida
Medical Superintendents - All ESIC Hospitals
Director ESIS Hospitals - All States
SSMC's/SMC's-All States

-REVISED INSTRUCTIONS-Regarding "Testing Of Drugs"-04

Sir/Madam,

In supersession to Hqrs letter of even no. dated 18/09/2014, I am directed to convey the Revised Instructions on Testing of Drugs as under:-

a) **All batches** of drugs/medicines supplied by each supplier under DG-ESIRC, shall be subjected to Quality Testing by Govt/Govt approved laboratories **at the time of receipt of supply**.

Additional Testing of drugs may also be undertaken at any time during the shelf life or whenever any defect is noticed.

Report with respect to the above must be submitted in the format given below within two working days.

Name of ESI Institution : _____

S. No	RC No	Name of Pharmaceutical Firm	Name of Item	Item No& Page No. As per RC	Batch No	D.O Mfg & D.O Expiry	Date of sampling

1. If authentic information regarding submission of specific batch of sample sent for testing is available with user unit, the same batch may not be sent for testing again.
2. For all samples declared **"Not Of Standard Quality"**, information along with self attested copy of the Test Report by Medical Officer Incharge of Store, be sent to Hqrs Office in the format given below with in a period of seven days from the date of receipt of report:

S. No	RC No	Name of Pharmaceutical Firm	Name of Item	Item No& Page No. As per RC	Batch No	D.O Mfg & D.O Expiry	Date of sampling	Report No.	Date of report

Compliance/ Action Taken Report must be submitted within the time specified above both in soft copy (Excel Format only) at dmc-rc@esic.nic.in and hard copy to ESIC Headquarter office.

This issues with the approval of Director General.

Yours faithfully,

21.1.15.

(Dr.Sangeeta Mathur)
Dy.Medical Commissioner(RC)

Copy to:

1. P.S to D.G/F.C/M.C/DMC (MS I)
2. WCM for uploading on ESIC website.
3. Dr Abhimanyu Panda, DMC (Systems)-dr.abhimanyu.panda@esic.in
4. Accounts Branch V, ESIC Hqrs Office.
5. Hindi Cell for translation.
6. Guard File.

21.1.15.

Dy.Medical Commissioner(RC)

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारतें सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी॰आई॰जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan,C.I.G. Marg,New Delhi-110002
www.esic.nic.in, ☎011-23234334,✉ dmc-rc@esic.nic.in

No. U-25/12/NSQ-141/2020-Med. V / 3 5 Dated: 07.09.2021

To,
Director (Med.) Delhi/ Director (Med.) Noida
Deans – All ESIC Medical Colleges
Medical Superintendent -All ESIC Hospitals.
Directors, ESI Schemes- All States

Sub: Testing of CPSU drugs procured through GeM Portal - reg.
Ref.: No. U-25/12/149/2020-Med. V Dated: 31.03.2021 (copy enclosed)
No. U-25/12/NSQ-141/2020-Med V dated: 29.07.2021 (copy enclosed)

Madam/Sir,

Pursuant to this office letter dated 31.03.2021 & 29.07.2021, it is reiterated that:

1. All user units are hereby informed that all drugs purchased through GeM Portal from CPSU firms under Pharmaceutical Purchase Policy are to be sent for random testing through Govt. Labs/Govt. approved Labs.
2. Action for drugs declared Not of Standard Quality 'NSQ' on testing to be undertaken as per:
   A. General Terms & Conditions of GeM and
   B. Terms & Conditions of GeM for CPSU Drugs
3. Issues related to Quality (NSQ) on procurement through GeM Portal, NSQ will be reported by user unit to GeM and ESIC, HQRS Office.
4. User units should determine Re-Order Level, Buffer Stock and consider lead times for delivery as per Terms & Conditions of GeM Portal.
5. All procurement should be done in adherence to the prescribed procedure through GeM & ensure maintaining adequate stock and quality medicines for smooth delivery of services to ESI beneficiaries.

This is for information and necessary action.

This issues with the approval of Medical Commissioner (Procurement).

Yours faithfully,

Encl: As above

(Jai Singh)
Assistant Director (RC)

Copy for information to: -

1. Shri Pranava Kumar, Dy. Director (PR) e-mail pranava.kumar@esic.in with request for uploading on ESIC website
2. Hindi Rajbhasha for translation
3. Guard file

Assistant Director (RC)

Not uploaded

सत्यमेव जयते

मुख्यालय, कर्मचारी राज्य बीमा निगम
HEADQUARTERS, EMPLOYEES' STATE INSURANCE CORPORATION
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-110002
PANCHDEEP BHAWAN: C.I.G. ROAD: NEW DELHI – 110 002
TelFax: 011-23234334, E-mail: dmc-rc@esic.nic.in

No. U-25/12/149/2020-Med. V [131] Dated: 31.03.2021

To,
Director (Med.) Delhi/ Director (Med.) Noida
Deans – All ESIC Medical Colleges
Medical Superintendent -All ESIC Hospitals.
Directors, ESI Schemes- All States

Sub: Procurement of CPSU drugs through GeM Portal only-reg.
Ref.: No. U-25/12/149/2020-Med. V Dated: 23.12.2020 & 11.01.2021, 17.02.2021 (copy enclosed)

Madam/Sir,

In continuation to letters issued by this office on the captioned subject, I am directed to convey the in-principle approval of Director General, ESIC to continue the **already initiated procedure for procurement of CPSU drugs through GeM Portal only.**

Henceforth, this shall be the prescribed procedure for procurement of all CPSU drugs exclusively from CPSU Firms under Pharmaceutical Purchase Policy.

It is also informed that drugs will be procured through DG ESIC RC 147/147A or any other RC released in future as backup RC for CPSU drugs **only after documenting** the Non-Supply/Part Supply by generating GeMAR&PTS certificate/Incident report/any other documentary evidence from GeM Portal.

All procurement regarding issues on GeM Portal, may kindly be escalated to GeM IT Helpdesk for resolution under intimation to ESIC, HQRS Office.

It is the sole responsibility of the Competent Authority to adhere to the prescribed procedure through GeM & ensure maintaining adequate stock for smooth delivery of services to ESI beneficiaries.

This issues with the approval of Director General.

Yours faithfully,

31.3.21

(Dr. Sangeeta Mathur)
Dy. Medical Commissioner (RC)

End: As above

Copy for information to: -

1. PPS/PS to FC
2. Shri Pranava Kumar, Dy. Director (PR) e-mail pranava.kumar@esic.in with request for uploading on ESIC website
3. Hindi Rajbhasha for translation
4. Guard file

31.3.21

Dy. Medical Commissioner (RC)

WUL

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी॰आई॰जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan,C.I.G. Marg,New Delhi-110002
www.esic.nic.in, ☎011-23234334, dmc-ro@esic.nic.in

No. U-25/12/NSQ-141/2020-Med. V – 303 Dated: 29.07.2021

To,
Director (Med.) Delhi/ Director (Med.) Noida
Deans – All ESIC Medical Colleges
Medical Superintendent -All ESIC Hospitals.
Directors, ESI Schemes- All States

Sub: Testing of CPSU drugs procured through GeM Portal - reg.
Ref.: **No. U-25/12/1[illegible]9/2020-Med. V Dated: 31.03.2021 (copy enclosed)**

Madam/Sir,

Pursuant to this office letter dated 31.03.2021, on the captioned subject, all user units are hereby advised to continue random testing of drugs purchased through GeM Portal from CPSU firms under Pharmaceutical Purchase Policy.

If, any product is found to be Not of Standard Quality "NSQ" on testing, it is hereby advised to act as per:

1. General Terms & Conditions of GeM and
2. Terms & Conditions of GeM for CPSU Drugs

All user units should ensure that such incidents and all other procurement regarding quality (NSQ) issues on GeM Portal, may kindly be escalated to GeM Help Desk for resolutions under intimation to ESIC, HQRS Office.

It is the sole responsibility of the Competent Authority to adhere to the prescribed procedure through GeM & ensure maintaining adequate stock and quality medicines for smooth delivery of services to ESI beneficiaries.

This issues with the approval of Medical Commissioner (Procurement).

Yours faithfully,

29.7.21.

(Dr. Sangeeta Mathur)
Dy. Medical Commissioner (RC)

Encl: As above

Copy for information to: -

1. Shri Pranava Kumar, Dy. Director (PR) e-mail: pranava.kumar@esic.in with request for uploading on ESIC website
2. Hindi Rajbhasha for translation
3. Guard file

29.7.21.

Dy. Medical Commissioner (RC)

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, dmo-rc@esic.nic.in

E-Office No. 278/ U-25/12/Drug Policy/ 2014-Med V/Pt-1 /605 Dated:17.01.2024

To,

Director (Medical) Delhi/Director (Medical) Noida
Deans & Medical Superintendents -All ESIC Hospitals
Regional Directors-All States
SMO's- All States
Director ESIS Hospitals -All States

Sub: Testing of quality of drugs approved in valid DGESIC Rate Contract/s - reg.

Sir/Madam,

Reference captioned subject, it is informed that maintenance of Quality plays a very important role in drugs issued to ESIC beneficiaries, the lack of procedure of which, has been a key observation in the recent Audit conducted by the CAG for several States.

In this context, kind attention is drawn towards the terms & conditions of DGESIC Rate Contract (Drugs & Dressings) w.r.t clause for 'Testing of Drugs' duly reproduced as below:

"Regular and random testing of drugs will be under taken by ESI from Govt./Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed.

The Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ bidder at regular interval to maintain and ensure the quality of drugs."

In reference to above, it is observed that ESI Institutions are not sending samples for testing regularly &/or submitting information of samples sent for testing to ESIC Hqrs office for which instructions were already issued vide letter no. U-25/12/Drug Policy/ 2014-Med V/Pt-1 /04 dated 21/01/2015.

It is again reiterated that:

1. Acceptance of supply of all drugs (Indian/Imported) procured through valid DG ESIC Rate Contracts should mandatorily be accompanied with In-House testing report and the same should be checked at Inspection by the nominated Inspecting officers.
2. All ESI Institutions should mandatorily send batches of drugs as samples for testing regularly to Govt./Govt. approved Laboratories, in adherence to terms & conditions of respective valid DG ESIC Rate Contract/s.
3. The quantity of batch/sample sent for testing and the receipt thereof, should be as per terms and conditions governing the local contracts for Testing, of respective Institution.

1/3.

4. The stock of respective drugs for which batches/samples have been sent for Quality testing, should be released for consumption after the receipt of Quality report.
5. The selection of samples sent for testing should be done prudently by the Medical Store keeping in context the Inventory Stock position, supply orders in pipeline, buffer stock, online information on ESIC website etc such that under no circumstances the withholding of the respective Batch sent for Testing till the receipt of report should result in 'Stock out' of the respective drug/s or result in frivolous Local Purchase.
6. It is mandatory to maintain records for both the samples sent for Testing by the Institution as well as that collected by the State Drug Inspector (as the case maybe).
7. Simultaneously, the information of the drugs sent for Testing and samples collected by the State Drug Inspector (as the case maybe) should be forwarded to the office of the Medical Commissioner of respective Zone and Med V Rate Contract Division, ESIC Hqrs office in the format below, by 5th of each coming month in soft copy (Excel Format only) to dmc-rc@esic.nic.in from the official ID of the Head of the Institution :

Name of ESI Institution: _____

S. No.	RC No.	Name of Pharmaceutical Firm	Name of Item	Item No. & Page No. as per RC	Drug License Number and place of production	Batch No	D.O Mfg & D.O Expiry	Date of sampling

8. ESI Institutions should mandatorily check ESIC website for the uploads regarding samples sent for testing. If authentic information regarding submission of specific batch of sample sent for testing is available with user unit, the same batch may not be sent for testing again.
9. For all samples declared **"Not of Standard Quality"**, information along with self-attested copy of the Test Report duly countersigned by Dy. Medical Superintendent/Medical Officer Incharge of Store should be sent to ESIC Hqrs office in the format given below with in a period of seven days form the date of receipt of report:

Name of ESI Institution: _____

S. No.	RC No.	Name of Pharmaceutical Firm	Name of Item	Item No. & Page No. As per RC	Drug License Number and place of production	Batch No	D.O Mfg & D.O Expiry	Date of sampling	Name of Laboratory/ Govt. agency reporting the NSQ	Report No.	Date of report

10. The data for samples sent for Testing from all ESI Hospitals within the respective State and any NSQ reported thereof should be mandatorily also sent to the office of the Medical Commissioner of the respective zone.
11. All ESI Institutions should initiate penal action (replacement of batch of drug with a different batch/ recovery, deduction of testing charges etc) as per terms and conditions of the DG ESIC Rate Contract.
12. **Quality assurance of drugs is not only an essential clause in the terms & conditions of the Rate Contracts but also plays a vital role in maintaining distribution of life saving drugs to patients.**

The above instructions are for mandatory adherence by all Heads of Institutions. Any legal repercussion arising in respect to non-adherence of Quality shall lie solely with the Heads of Institution.

This issues with the approval of Medical Commissioner.

Warm regards,

17.01.2024.

(Dr. Sangeeta Mathur)

Dy. Medical Commissioner (RC)

उप चिकित्सा आयुक्त (आर. सी.)/Dy. Medical Commissioner (RC)
क.रा.बी.नि. (मु.)/E.S.I. Corporation (H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी. आई. जी. मार्ग., नई दिल्ली–2
Panchdeep Bhawan, CIG Marg, New Delhi-2

Copy for information to:

1. PPS to DG,FC,CVO
2. PS to Medical Commissioner (Procurement & SST)
3. PS to Medical Commissioner (Medical Services & Medical Education)
4. Medical Commissioner of respective Zones.
5. DMC (MS) with request for addition of number of samples sent for testing and any NSQ reported in the monthly DO letter sought from ESI Institutions.
6. All DG ESIC RC approved Pharmaceutical firms for compliance to supplying the respective item under the Drug License Number and plant as quoted in the Tender.

17.01.2024.

Dy. Medical Commissioner (RC)

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan,C.I.G. Marg,New Delhi-110002
www.esic.gov.in 011-23604773 emc-rc@esic.nic.in

E-Office No. 278/ U-25/12/Drug Policy/2014-Med V/Pt-I/686 Dated:-13.02.2024

To,

Director (Medical) Delhi/ Director (Medical) Noida
Deans & Medical Superintendents -All ESIC Hospitals
Regional Directors – All States
SMO's- All States
Director ESIS Hospitals -All States

CORRIGENDUM

Sub: Testing of quality of drugs approved in valid DGESIC Rate Contract/s reg.

Ref: Web Upload issued vide Console No. 15630 dated 17.01.24

Sir/ Madam,

Pursuant to the web upload issued from ESIC Hqrs Office vide Console No.15630 dated 17.01.24 pls find below a Corrigendum w.r.t. Point No. 1 of the said web upload, detailed as below:

Point -1	Corrigendum- Point to be read as
"Acceptance of supply of all drugs (Indian/Imported) procured through valid DG ESIC Rate Contracts should mandatorily be accompanied with **In-House testing report** and the same should be checked at Inspection by the nominated Inspecting officers"	Acceptance of supply of all drugs (Indian/Imported) procured through valid DG ESIC Rate Contracts should mandatorily be accompanied with : • Test Report for the particular batch of medicines tested by the Government/ Government approved Laboratories along with each supply by the approved Rate Contract Holder and the same should be checked at Inspection by the nominated Inspecting officers. • For Imported items:- In-house test report of Principal manufacturer with each batch of supply by the approved Pharmaceutical firm and the same should be checked at Inspection by the nominated Inspecting officer.

This issues with the approval of Medical Commissioner.

With regards,

12.2.24

Dy. Medical Commissioner (RC)

उप चिकित्सा आयुक्त (RC)
क.रा.बी.नि. (मु. H.Q.)
श्रम एवं रोजगार मंत्रालय, भारत सरकार
Ministry of Labour & Employment, Govt. of India
पंचदीप भवन, सी. आई. जी. मार्ग, नई दिल्ली–2
Panchdeep Bhawan, C.I.G. Marg, New Delhi-2
Dy. Medical Commissioner (RC)

Copy for information to:

1. Website Content Manager with request for uploading on ESIC website.
2. Guard file

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23804773, dmc-rc@esic.nic.in

E-Office No. 278/ U-25/12/Drug Policy/2014-Med V/Pt-I/ 708 Dated:-26.02.2024

To,

Director (Medical) Delhi/ Director (Medical) Noida
Deans & Medical Superintendents -All ESIC Hospitals
Regional Directors – All States
SMO's- All States
Director ESIS Hospitals -All States

Sub: Testing of quality of drugs approved in valid DGESIC Rate Contract/s reg.

Ref: ESIC Hqrs Web-upload dated 17.01.2024 followed by corrigendum dated 13.02.2024 (copies enclosed).

Sir/ Madam,

Reference captioned subject, kind attention is hereby drawn towards the web-upload Console Sl. No. 15630/2024 dated 17.01.2024 and corrigendum dated 13.02.2024.

In this context, it is informed that no information w.r.t. testing of quality of drugs has been received from any ESI Institutions for the month of January'2024 in the required format except the following:

1. ESIC Hospital Adityapur
2. CMS, ESI Scheme Ahmedabad.

Hence, it is again reiterated that in order to monitor the quality of drugs, ESI institutions are once again instructed by the Medical Commissioner (Procurement) to submit the required information w.r.t the drugs sent for testing/ samples collected by the State Drug Inspector (as the case maybe) to the office of the Medical Commissioner of respective Zone and Rate Contract Cell (Med-V), ESIC Hqrs Office strictly in the format given below by 5th of each month in soft copy (Excel Format only) to dmc-rc@esic.nic.in:

S. No.	RC No.	Name of Pharmaceutical Firm	Name of Item	Item No. & Page No. as per RC	Batch No	D.O Mfg. & D.O Expiry	Date of Sampling

This issues with the approval of Medical Commissioner (Procurement).

With regards,

26.2.24.

Dy. Medical Commissioner (RC)

Copy for information to:

1. Zonal Medical Commissioner for information.
2. ICT Division with a request to create a separate section on ESIC website for circulars/information of drugs sent for testing and testing report thereof.
3. Website Content Manager with request for uploading on ESIC website.
4. Guard file

26.2.24

Dy. Medical Commissioner (RC)

WEB-UPLOAD

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, dmo-pc@esic.nic.in

U-25/12/Janaushadhi(PMBJP)/2023-Med.V (E-511943)/297 Dated: 16/08/2024

To

- Director (Medical) Delhi/Noida
- Dean's-All ESI PGIMSR's & Medical Colleges
- Medical Superintendent's- All ESIC Hospitals
- Directors, Insurance Medical Services(DIMS)-ESI Scheme, All States & UT's
- Regional Director's-All States & UT's

Sub: Procurement of Medicines in ESIC from Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)-reg.

Sir/Madam

As you are aware, currently drugs are being procured by ESI Institutions through valid DG ESIC Central Rate Contracts, CPSU drugs through GeM and Local Purchase of Medicines mostly from empanelled Chemists. The procurement of Non-RC drugs through local purchase has been a matter of concern as the percentage of its procurement has increased over the years and mostly consists of branded drugs leading to increased burden of its cost. This has been reviewed at the highest level and Standing Committee of ESIC in its 230th Meeting held on 31/01/2024 has recommended procurement of non-RC drugs from "Jan Aushadhi" system.

Employees' State Insurance Corporation,Hqrs has signed an MoU with Pharmaceuticals & Medical Devices Bureau of India (PMBI, operating agency for Pradhan Mantri Janaushadhi Pariyojna under Janaushadhi Campaign) for supply of Medicines to ESIC (copy enclosed).

The supply of Medicines and billing to respective ESIC & ESIS Institutions i.e Medical College, Hospitals, State Directorate, Dispensaries, DCBO and other ESI procuring units pan India shall be made by PMBI through their Authorized Distribution Channel Partner on issue of purchase order/Requisition from Authorized representative of ESIC & ESIS Institutions. The detail of PMBI Authorized Distribution Channel Partner in respective State/UT are enclosed.

In context to above, ESIC and ESIS Institutions (Medical Colleges, Hospitals, State Directorates, Dispensaries, DCBO's and other ESI procuring units pan India) are requested to sign an MoU between ESIC/ESIS Institution and PMBI's Authorized Distribution Channel Partner of your State/UT OR nearby State/UT as per format enclosed.

U-25/12/Janaushadhi(PMBJP)/2023-Med.V

The Standard Operating Procedure(SOP's) for procurement of medicines in ESIC & ESIS Institutions from Pradhan Mantri Bhartiya Janaushadhi Pariyojana(PMBJP) is enclosed for ready reference.

Deans/MSs/ DIMS/D(M)D/D(M)N/AMO/ Head of ESIC & ESIS Institutions are requested to ensure the compliance of above instructions with immediate effect.

This issues with the approval of Director General.

Regards,

Enclosures: As above

Signed by Cecil Christopher Khakha
Date: 16-08-2024 13:35:34

(Dr. C.C. Khakha)
Medical Commissioner (Procurement)

Copy to:

1. PPS to DG/FC/CVO for information
2. PPS/PS to MC(MA)/ MC(ME)/MC(MS) for information
3. **All Zonal Medical Commissioners for implementation & monitoring of procurement of Non-RC drugs from Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) in all ESIC and ESIS Institutions under their jurisdiction.**
4. Website content manager with a request to upload on ESIC, Hqrs website.

Medical Commissioner(Procurement)

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, dmc-rc@esic.nic.in

U-25/12/Janaushadhi(PMBJP)/2023-Med.V (E- 511943) Dated:
Web-upload

To

- Director (Medical) Delhi/Director (Medical) Noida
- Dean's-All ESI PGIMSR's & Medical Colleges
- Medical Superintendent's- All ESIC Hospitals
- Directors, Insurance Medical Services(DIMS)-ESI Scheme, All States & UT's
- Regional Director's-All States & UT's

Sub: Procurement of Medicines in ESIC from Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)-reg.

Ref.: Web-upload vide console serial no.17954/2024 dated 16.08.2024.

Sir/Madam

This is in continuation of earlier letter of even no. dated 16.08.2024, the following amendment may please be noted: -

S.No.	Existing Clause of MoU for Drug Testing	Amended Clause may be read as
1	**Clause No. 9 of MoU signed between ESIC Hqrs and PMBI**: "ESIC & ESIS Institution reserve the right to test the supplied goods and will send random samples for testing the quality if there is any suspicion. If any batch is declared –'Not of Standard Quality' the cost of the entire batch will be refunded, including stock that has been already consumed"	**ESIC and ESIS Institution reserve the right to test the supplied goods and will send random samples for testing the quality if there is any suspicion. If any batch is declared –'Not of Standard Quality' by PMBI, the cost of the remaining stock will be refunded, i.e. excluding stock that has been already consumed and all the NSQ stock must be returned physically to its purchase source for issuing the credit note**".
2	**Clause 9 of MoU between ESI Institution/s and authorized distribution channel partner of PMBI:** "If any batch is declared-Not of Standard Quality, the cost of the entire batch will be refunded, including the stock which has been already consumed"	**If any batch is declared –'Not of Standard Quality' by PMBI, the cost of the remaining stock will be refunded, i.e. excluding stock that has been already consumed and all the NSQ stock must be returned physically to its purchase source for issuing the credit note**".

Further, it is informed that PMBI has the robust mechanism of testing of medicines procured, through NABL empaneled labs and all the batches of all the medicines which are supplied are duly pre-tested. In any case of quality suspicion observed by ESI Institution/s , the lab reports shall be provided on demand to ESIC & ESIS Institutions by PMBI.

Rest of the Terms & Conditions of the MoU will remain the same.

With Regards,

Enclosures: As above

Signed by Cecil Christopher Khakha
Date: 19-09-2024 18:07:49

(Dr. C.C. Khakha)
Medical Commissioner
(Procurement)

Copy to:

1. PPS to DG/FC/CVO for information
2. PPS/PS to MC(MA)/ MC(ME)/ MC(MS) for information
3. All Zonal Medical Commissioners for implementation & monitoring of procurement of Non-RC drugs from Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) in all ESIC and ESIS Institutions under their jurisdiction.
4. Sh. Ravikant Tiwari, General Manager, Pharmaceuticals & Medical Devices Bureau of India (PMBI)
5. Website content manager with a request to upload on ESIC, Hqrs website.

U-25/12/drugpolicy/2021/Med-V

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, dmmcr@esic.nic.in

U-25/12/drug policy/2021/Med-V(E-278) /355 Dated:

To,

Director (Medical) Delhi/ Director (Medical) Noida

Deans/Medical Superintendents -All ESIC Medical College & Hospitals

Regional Directors – All States/UT's

DIMS-All States/UT's

SMO's- All States/UT's

Subject: Testing of quality of drugs approved in valid DGESIC Rate Contract/s -reg.

Ref: ESIC Hqrs Web-upload vide console no. 15630/2024 dated 17.01.2024,15922/2024 dated 13.02.2024,16045/2024 dated 27.02.2024 .

Sir/Madam

Reference captioned subject and in continuation to the earlier order , pertaining to testing of quality of drugs approved in valid DGESIC Rate Contract (Copies enclosed).

In this context, it is informed that information regarding quality testing of drugs have not been received by this office on the monthly basis from many ESI Institutions in the required format provided by ESIC Hqrs office.

Hence, it is again reiterated that, in order to monitor the quality of drugs **"under clause Testing of Drugs-Quality Control"** in respective valid DG ESIC Rate Contracts, ESI institutions are once again requested to submit the required information w.r.t the drugs sent for testing/ samples collected by the State Drug Inspector (as the case may be) to office of the Medical Commissioner of respective Zone and Rate Contract Cell (Med-V), ESIC Hqrs Office strictly in the format given below by **5th of each month** in soft copy (Excel Format only) .

Name of ESI Institution.....

S. No.	RC No.	Name of Pharmaceutical Firm	Name of Item	Item No. & Page No. as per RC	Batch No.	D.O Mfg. & D.O Expiry	Date of Sampling/Date of sample sent for Testing

- If sample declared "Not Of Standard Quality" ,information along with self-attested copy of the Test Report by Medical Officer (In charge of Store), be sent to Hqrs Office in the format given below within a period of 05 days from the date of receipt of report.

U-25/12/drugpolicy/2021/Med-V

I/1793273/2024

Name of ESI Institution.....

S. No.	RC No.	Name of Pharmaceutical Firm	Name of Item	Item No. & Page No. as per RC	Batch No.	D.O Mfg. & D.O Expiry	Date of Sampling	Name of Laboratory/Govt. agency reporting the NSQ	Report No.	Date of Report

Compliance/Action Taken Report must be submitted within the time specified above in **soft copy** (Excel Format only) at dmc- rc@esic.nic.in and **hard copy** to ESIC headquarters office.

This issues with the approval of Medical Commissioner (Procurement).

Yours Sincerely

Signed by Neeta Garbiyal
Date: 07-10-2024 19:02:05

Dy. Medical Commissioner (RC)

Enclosures: As above

Copy to:

1. Medical Commissioner (North-East Zone, South Zone, West Zone, East Zone, North Zone) for information.
2. ICT Division of ESIC HQ is requested to create a separate section on ESIC website for updating information pertaining to drugs sent for testing by ESI/Sample collected by Drug department from ESI.
3. Website Content Manager with request for uploading on ESIC website.
4. Guard file

कर्मचारी राज्य बीमा निगम
(श्रम एवं रोज़गार मंत्रालय,भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)

मुख्यालय/HEADQUARTERS'
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in, ☎011-23604773, ✉ dmc-rc@esic.nic.in

No. U-25/12/Janaushadhi(PMBJP)/2023-Med.V(E-511943) Dated: 07.03.2025

To,
Director (Medical) Delhi/Noida,
Dean-ESI PGIMSR's/ ESIC Medical Colleges /Dental Colleges
Medical Superintendent – All ESIC & ESIS Hospitals,
Director, ESI Scheme – All States & UTs.

Sub:-Procurement of Medicines in ESIC from Pradhan Mantri Bhartiya Janaushadhi Pariyojana(PMBJP)-reg.

Ref: Web-upload vide Console Sl. No. 18257/2024 and 17954/2024 respectively on ESIC Hqrs Website (copy enclosed).

Sir/Madam

Reference captioned subject, in order to ensure the quality of supplied drugs, it is hereby requested to undertake regular and random testing of the drugs supplied by the PMBI Authorized distribution channel partners at regular interval.

This is for your information and necessary action.

This issues with the approval of Medical Commissioner (Procurement).

Digitally signed by
Neeta Garbiyal
Date: 10-03-2025
18:39:44

By: Medical Commissioner (RC/PC)